2Evanswe P. Acute lymphoblastic leukemia [ J ]. N Ensl J Med, 1998, 339(9) :605-615. 被引量：1
3Parker WB,Secrist JA, Waud WR, et al. Purine nucleoside analogues in development for the treatment of cancer [ J ]. Curropin Investing Drugs, 2004,5 ( 6 ) : 592 -596. 被引量：1
4Gandhi V, Keating MJ, Bate G. Nelarabine [ J ]. Nat Rev Drug Diseov, 2006,5(1) :17-18. 被引量：1
1Keating MJ, Kantarjian H, Talpaz M, et al. Fludarabine: a new agent with major activity against Chronic lymphocytic leukemia [ J ]. Blood, 1989, 74: 19-25. 被引量：1
2Struck RF, Shormacy AT, Kirk MC, et al. Identification of metabolities of 9-β-D-arabinofuranosyl-2-fluoroadenine, an antitumor and antiviral agent [ J ].Biochem. Pharmacol, 1982, 31:1975-1978. 被引量：1
3Ficarra R, Calabro ML, Tommasini S, et al. Determination of fludarabine in a pharmaceutical formulation by LC [ J ]. Journal of Pharmaceutical and Biomedical Anlysis , 1999, 21:1077-1081. 被引量：1
5PARKER WB, SECRIST JA ,WAUD WR,et al. Purine nucleoside analogues in development for the treatment of cancer [J]. Curr Opin lnvestig Drugs ,2004,5 (6):592 - 596. 被引量：1
6KISOR DF, PLUNKETT W, KURTZBERG J. Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies [J]. J Clin Oncol,2000,18(5) :995 - 1003. 被引量：1
7RODRIGUEZ CO, Jr., STELLRECHT CM, GANDHI V, et al.Mechanisms for T-cell selective cytotoxicity of arabinosylguanine[J]. Blood, 2003,102 (5): 1842 - 1848. 被引量：1
8GANDHI V, KEATING MJ, BATE G. Nelarabine[J]. Nat Rev Drug Discov ,2006,5(1): 17 - 18. 被引量：1
9RODRIGUEZ CO, Jr. , GANDHI V. Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step [J]. Cancer Res, 1999,59 (19):4937 - 4943. 被引量：1
10BERG SL, BLANEY SM, DEVIDAS M,et al. Phase Ⅱ study of nelarabine (compound 506 U78 ) in children and young adults with refractory T-cell malignancies:a report from the Children's Oncology Group [J]. J Clin 0ncol,2005,23(15):3376 - 3382. 被引量：1
